News | July 27, 2012

Bard Completes Enrollment in IDE Drug-Coated Balloon Trial

Large continuation registry study initiated to monitor patients treated with Lutonix drug-eluting balloon

July 27, 2012 — C. R. Bard Inc. announced that its Lutonix technology center has completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial. The purpose of the pivotal investigational device exemption (IDE) trial is to compare the safety and efficacy of the Lutonix drug-coated PTA dilatation catheter (DCB) to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD).

LEVANT 2 was the first drug-coated balloon IDE trial approved by the U.S. Food and Drug Administration (FDA). The trial randomized 476 patients with diseased femoropopliteal leg arteries at 55 centers worldwide. Randomized patients in LEVANT 2 will be followed for five years and independent laboratories will verify trial outcomes. The Lutonix DCB was first studied in the LEVANT 1 trial, a 101-patient first-in-human multicenter randomized trial. The company expects to release two-year follow-up data from LEVANT 1 later this year.

In addition, the company also announced that it has obtained FDA approval and initiated enrollment in the LEVANT 2 continued access registry study. The first subject was enrolled June 19, 2012 in Belgium. This new study will enroll an additional 650 patients at 70 centers worldwide. Together with the randomized patient cohort, the company expects the combined studies to deliver a scientifically significant dataset for this first-of-its-kind technology.

The co-principal investigators for the LEVANT 2 randomized clinical trial are Kenneth Rosenfield (Massachusetts General Hospital, Boston) and Dierk Scheinert (Heart Center Leipzig/Park Hospital, Leipzig, Germany).

“LEVANT 2 has been carried out to a degree of academic rigor that is unprecedented in this disease state," said Rosenfield. "The controlled design of this trial is one that will offer us the first-in-kind results and insights on the role of drug-coated balloons for this population.”

For more information: www.crbard.com

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init